search
Back to results

Brief, Remote Treatment of Youth Injection Phobia and Measurement of Novel, Disorder-congruent Cognitive Bias Tasks

Primary Purpose

Anxiety Disorder of Childhood

Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Remote, intensive intervention for injection phobia
Sponsored by
Boston University Charles River Campus
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Anxiety Disorder of Childhood focused on measuring intensive treatment, remote treatment, cognitive bias, measurement

Eligibility Criteria

8 Years - 16 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • A clinical diagnosis of specific phobia- blood, injection-injury subtype
  • Age between 8 and 16
  • Spoken and reading fluency in English
  • Third grade reading ability
  • Parental availability to participate in treatment study sessions
  • Parental spoken and reading fluency in English.

Exclusion Criteria:

  • A comorbid, previously assigned diagnosis of attention deficit hyperactivity disorder (ADHD), major depressive disorder (MDD), generalized anxiety disorder (GAD) OR significant parental endorsement of inattentiveness, hyperactivity, prolonged depressed mood, or pervasive generalized worries that are interfering with the child's life at the phone screen level
  • A diagnosed learning disorder in reading or information processing
  • Parent-reported child unwillingness or lack of ability to participate in cognitive bias tasks (e.g., looking at needle or injection-related imagery, reading basic stories about needles or blood draws)
  • Previous and/or concurrent participation in CBT-based, exposure therapy for the fear of injections.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm 3

    Arm Type

    Experimental

    Experimental

    Experimental

    Arm Label

    One week baseline

    Two week baseline

    Three week baseline

    Arm Description

    Participants randomized to baseline one will go through a one-week baseline period before beginning the treatment.

    Participants randomized to baseline two will go through a two-week baseline period before beginning the treatment.

    Participants randomized to baseline three will go through a three-week baseline period before beginning the treatment.

    Outcomes

    Primary Outcome Measures

    Change in Fear and Avoidance Ratings
    Participants will rate their level of fear and avoidance in response to the hypothetical scenario of needing to get a shot. This measure consists of two items, both rated on a scale from 0 (not at all) to 8 (very, very much). The study is interested in looking at the changes in these ratings from the baseline period to the post treatment and two-week follow-up period.

    Secondary Outcome Measures

    Remote Treatment Acceptability/Feasibility measure
    This measure was adapted for the current study, but is based on the Perceptions of Treatment Questionnaire (Mattis & Ollendick, 1997). The current measure assesses parent's perceptions of the speed, convenience, and helpfulness of the study treatment. The measure consists of 15 items, 11 of which are rated on a Likert scale and 4 of which are free response items. The likert scale items are rated on a 7-point scale, from extremely not (0) to extremely (6).
    Measure of the acceptability and feasibility of cognitive bias tasks
    This measure was developed for the purposes of the current study and obtains participants' perspectives about the length, comprehensibility, ease of use, construct validity, and entertainment value of the attentional, interpretation, and memory bias tasks. This measure includes both Likert scale response (9-pt. scale from 0, not at all to 8, very, very much) and free-response items to gain a comprehensive picture of the strengths and limitations of the newly adapted or developed cognitive bias tasks. This measure contains three subscales, each of which corresponds to one of the three cognitive bias tasks (attentional, interpretation, memory). The attentional bias task subscale contains 11 items, the interpretation bias subscale contains 8 items, and the memory bias subscale contains 9 items. The total scale consists of 28 items.
    Analysis of test-retest reliability and treatment sensitivity of the attentional bias task
    Once data collection is complete, it will be possible to analyze the test-retest reliability of the attentional bias task. This will be accomplished by assessing the association between attentional bias indices at pre-treatment and at the beginning of the first session, before treatment has been introduced. Additionally, it will be possible to inspect the treatment sensitivity of the attentional bias task by assessing the difference in magnitude of attentional bias indices before treatment and after treatment at the two-week follow-up time-point.
    Analysis of test-retest reliability and treatment sensitivity of the interpretation bias task
    Once data collection is complete, it will be possible to analyze the test-retest reliability of the interpretation bias task. This will be accomplished by assessing the association between interpretation bias indices at pre-treatment and at the beginning of the first session, before treatment has been introduced. Additionally, it will be possible to inspect the treatment sensitivity of the interpretation bias task by assessing the difference in magnitude of interpretation bias indices before treatment and after treatment at the two-week follow-up time-point.
    Analysis of test-retest reliability and treatment sensitivity of the memory bias task
    Once data collection is complete, it will be possible to analyze the test-retest reliability of the memory bias task. This will be accomplished by assessing the association between the memory bias index at pre-treatment and at the beginning of the first session, before treatment has been introduced. Additionally, it will be possible to inspect the treatment sensitivity of the memory bias task by assessing the difference in magnitude of the memory bias index before treatment and after treatment at the two-week follow-up time-point.

    Full Information

    First Posted
    June 16, 2021
    Last Updated
    July 12, 2021
    Sponsor
    Boston University Charles River Campus
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT04972006
    Brief Title
    Brief, Remote Treatment of Youth Injection Phobia and Measurement of Novel, Disorder-congruent Cognitive Bias Tasks
    Official Title
    Investigating the Acceptability, Feasibility, and Preliminary Efficacy of a Brief, Remote Treatment for Youth Injection Phobia and the Measurement of Cognitive Biases in Youth
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    July 2021
    Overall Recruitment Status
    Unknown status
    Study Start Date
    July 2021 (Anticipated)
    Primary Completion Date
    June 2022 (Anticipated)
    Study Completion Date
    June 2022 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Boston University Charles River Campus

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    This study is investigating the acceptability, feasibility, and preliminary efficacy of a brief, remote treatment for youth injection phobia. It will also be examining the acceptability, feasibility, and initial psychometric properties of three cognitive bias measures adapted or newly developed for youth injection fear.
    Detailed Description
    This study aims to investigate the acceptability, feasibility, and efficacy of a brief, remote treatment for youth injection phobia. There is a pressing need to increase the accessibility, reach, and efficacy of treatments for youth injection fear, as this fear affects approximately 11% of youth and can prevent them from receiving necessary medical procedures or vaccinations. Developing and validating the efficacy of treatments for youth injection fear that are time-efficient, convenient, and broadly accessible will facilitate more widespread targeting of this fear in youth, which could have a meaningful impact on youths' ability to receive medical treatments that involve injections or blood draws. Thus far, separate evidence bases have formed to support the efficacy of brief, intensive treatments for youth specific phobias and other anxiety disorders AND the efficacy of remotely delivered treatments for a range of youth anxiety disorders. However, studies have not yet combined these approaches to investigate their efficacy for treating youth injection phobia. The current study thus serves as the first to specifically examine the clinical utility of using a combined intensive and remote approach to treat youth injection phobia. Investigation into the treatment's impact on youth injection fear will be complemented by information, provided by youths' parents, about the treatment's convenience, acceptability, speed, suitability for the child's specific presentation, and overall helpfulness. Lastly, as a first step towards better understanding the cognitive processing variables that influence the development and maintenance of youth injection fear, the current study will examine the initial acceptability, feasibility, and psychometric properties of adapted or newly developed measures of attentional, interpretation, and memory bias. This study will use a multiple baseline design in which up to 18 youth will be randomly assigned to a one-, two-, or three-week baseline period before beginning the brief, remote intervention. Treatment will consist of two sessions in which the first session provides education about anxiety and lasts approximately 1.5 hours, and the second session consists of gradual exposure to injection-related stimuli and lasts approximately three to four hours. Throughout the study period, youth will complete various measures related to injection fear and related constructs as well as the cognitive bias tasks at three separate time-points.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Anxiety Disorder of Childhood
    Keywords
    intensive treatment, remote treatment, cognitive bias, measurement

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Model Description
    This study uses a multiple baseline design in which participants are assigned to either a one-week, two-week, or three-week baseline period before beginning the study treatment. Participants in all three baseline groups receive the same treatment, both in dose and form.
    Masking
    None (Open Label)
    Masking Description
    No masking
    Allocation
    Randomized
    Enrollment
    18 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    One week baseline
    Arm Type
    Experimental
    Arm Description
    Participants randomized to baseline one will go through a one-week baseline period before beginning the treatment.
    Arm Title
    Two week baseline
    Arm Type
    Experimental
    Arm Description
    Participants randomized to baseline two will go through a two-week baseline period before beginning the treatment.
    Arm Title
    Three week baseline
    Arm Type
    Experimental
    Arm Description
    Participants randomized to baseline three will go through a three-week baseline period before beginning the treatment.
    Intervention Type
    Behavioral
    Intervention Name(s)
    Remote, intensive intervention for injection phobia
    Intervention Description
    The intervention consists of a 1.5 hour session that provides youth with education about anxiety and a 3 to 4 hour session consisting of graduated exposure to injection fear.
    Primary Outcome Measure Information:
    Title
    Change in Fear and Avoidance Ratings
    Description
    Participants will rate their level of fear and avoidance in response to the hypothetical scenario of needing to get a shot. This measure consists of two items, both rated on a scale from 0 (not at all) to 8 (very, very much). The study is interested in looking at the changes in these ratings from the baseline period to the post treatment and two-week follow-up period.
    Time Frame
    This is a daily measure. Participants will complete it every day for the duration of the study period, which will range between 5 and 7 weeks depending on the participant's baseline assignment.
    Secondary Outcome Measure Information:
    Title
    Remote Treatment Acceptability/Feasibility measure
    Description
    This measure was adapted for the current study, but is based on the Perceptions of Treatment Questionnaire (Mattis & Ollendick, 1997). The current measure assesses parent's perceptions of the speed, convenience, and helpfulness of the study treatment. The measure consists of 15 items, 11 of which are rated on a Likert scale and 4 of which are free response items. The likert scale items are rated on a 7-point scale, from extremely not (0) to extremely (6).
    Time Frame
    This measure will be administered at the two week follow-up timepoint.
    Title
    Measure of the acceptability and feasibility of cognitive bias tasks
    Description
    This measure was developed for the purposes of the current study and obtains participants' perspectives about the length, comprehensibility, ease of use, construct validity, and entertainment value of the attentional, interpretation, and memory bias tasks. This measure includes both Likert scale response (9-pt. scale from 0, not at all to 8, very, very much) and free-response items to gain a comprehensive picture of the strengths and limitations of the newly adapted or developed cognitive bias tasks. This measure contains three subscales, each of which corresponds to one of the three cognitive bias tasks (attentional, interpretation, memory). The attentional bias task subscale contains 11 items, the interpretation bias subscale contains 8 items, and the memory bias subscale contains 9 items. The total scale consists of 28 items.
    Time Frame
    This measure will be administered at the two week follow-up timepoint.
    Title
    Analysis of test-retest reliability and treatment sensitivity of the attentional bias task
    Description
    Once data collection is complete, it will be possible to analyze the test-retest reliability of the attentional bias task. This will be accomplished by assessing the association between attentional bias indices at pre-treatment and at the beginning of the first session, before treatment has been introduced. Additionally, it will be possible to inspect the treatment sensitivity of the attentional bias task by assessing the difference in magnitude of attentional bias indices before treatment and after treatment at the two-week follow-up time-point.
    Time Frame
    This analysis will include data points from the pre-baseline assessment, the beginning of the first session, and the two week follow-up timepoint.
    Title
    Analysis of test-retest reliability and treatment sensitivity of the interpretation bias task
    Description
    Once data collection is complete, it will be possible to analyze the test-retest reliability of the interpretation bias task. This will be accomplished by assessing the association between interpretation bias indices at pre-treatment and at the beginning of the first session, before treatment has been introduced. Additionally, it will be possible to inspect the treatment sensitivity of the interpretation bias task by assessing the difference in magnitude of interpretation bias indices before treatment and after treatment at the two-week follow-up time-point.
    Time Frame
    This analysis will include data points from the pre-baseline assessment, the beginning of the first session, and the two week follow-up timepoint.
    Title
    Analysis of test-retest reliability and treatment sensitivity of the memory bias task
    Description
    Once data collection is complete, it will be possible to analyze the test-retest reliability of the memory bias task. This will be accomplished by assessing the association between the memory bias index at pre-treatment and at the beginning of the first session, before treatment has been introduced. Additionally, it will be possible to inspect the treatment sensitivity of the memory bias task by assessing the difference in magnitude of the memory bias index before treatment and after treatment at the two-week follow-up time-point.
    Time Frame
    This analysis will include data points from the pre-baseline assessment, the beginning of the first session, and the two week follow-up timepoint.

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    8 Years
    Maximum Age & Unit of Time
    16 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: A clinical diagnosis of specific phobia- blood, injection-injury subtype Age between 8 and 16 Spoken and reading fluency in English Third grade reading ability Parental availability to participate in treatment study sessions Parental spoken and reading fluency in English. Exclusion Criteria: A comorbid, previously assigned diagnosis of attention deficit hyperactivity disorder (ADHD), major depressive disorder (MDD), generalized anxiety disorder (GAD) OR significant parental endorsement of inattentiveness, hyperactivity, prolonged depressed mood, or pervasive generalized worries that are interfering with the child's life at the phone screen level A diagnosed learning disorder in reading or information processing Parent-reported child unwillingness or lack of ability to participate in cognitive bias tasks (e.g., looking at needle or injection-related imagery, reading basic stories about needles or blood draws) Previous and/or concurrent participation in CBT-based, exposure therapy for the fear of injections.
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Alicia R Fenley, MA
    Phone
    8502943327
    Email
    afenley@bu.edu
    First Name & Middle Initial & Last Name or Official Title & Degree
    Donna Pincus, PhD
    Phone
    6173539610
    Email
    dpincus@bu.edu
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Alicia Fenley, MA
    Organizational Affiliation
    Boston University
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    No
    IPD Sharing Plan Description
    No plan to share individual participant data with other researchers.

    Learn more about this trial

    Brief, Remote Treatment of Youth Injection Phobia and Measurement of Novel, Disorder-congruent Cognitive Bias Tasks

    We'll reach out to this number within 24 hrs